Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ALL patients' liver toxicities linked to antibiotics, other therapies

Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.

Publish date:

Key clinical point: Liver toxicity with pegylated asparaginase (PEG-ASP) may be linked to concomitant chemotherapeutics or antibiotics in ALL.

Major finding: Idarubicin was associated with a higher risk of grade 3 or 4 hepatotoxicity, and vincristine was associated with a borderline risk.

Study details: Retrospective review of 51 PEG-ASP dosing events in 26 adult patients with ALL.

Disclosures: The study was internally funded. The authors reported having no relevant conflicts of interest.

Source: Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.

Read the article.

Citation:

Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.

This Week's Must Reads